Global Action Plan on Antimicrobial Resistance

Global Action Plan on Antimicrobial Resistance
Name	Global Action Plan on Antimicrobial Resistance
Adopted	2015
Adopters	World Health Organization, Food and Agriculture Organization of the United Nations, World Organisation for Animal Health
Location	Geneva
Language	English language

Global Action Plan on Antimicrobial Resistance is an international policy framework established in 2015 to coordinate responses to the rising threat of antimicrobial resistance. It was endorsed at a high-level meeting of the World Health Organization, the United Nations, and allied agencies and has been referenced in subsequent summits such as the G20 Rome Summit (2021) and dialogues involving the United Nations General Assembly and World Health Assembly. The plan interfaces with global instruments like the Sustainable Development Goals and engages actors from public health, agriculture, and pharmaceutical sectors.

Background and Rationale

The plan arose amid mounting evidence from surveillance networks such as the European Centre for Disease Prevention and Control and the Centers for Disease Control and Prevention that resistant pathogens—including Mycobacterium tuberculosis, Staphylococcus aureus, and Escherichia coli—were undermining gains from interventions following eras defined by advances like the Penicillin discovery and the development of antibiotics. Reports by entities including the O'Neill report and analyses by the World Bank highlighted economic and health system impacts similar to past shocks like the 2008 financial crisis in scale. Cross-sectoral drivers implicated practices tied to industrial agriculture, veterinary medicine, and pharmaceutical supply chains linked to regions such as South Asia and Sub-Saharan Africa.

Objectives and Strategic Priorities

The plan sets strategic priorities aligning with targets found in instruments like the International Health Regulations (2005) and frameworks used by UNICEF and World Food Programme. Core objectives include optimizing antimicrobial use in settings exemplified by the National Health Service (England) stewardship programs, strengthening surveillance systems akin to those run by Public Health England and the European Medicines Agency, and promoting innovation models similar to prize incentives seen in XPRIZE competitions. It also emphasizes infection prevention modeled on protocols from Médecins Sans Frontières and Bill & Melinda Gates Foundation-funded initiatives, and capacity-building initiatives comparable to Global Fund investments to support low-resource contexts like Kenya and Bangladesh.

Implementation Framework and Activities

Implementation leverages mechanisms used in past global efforts such as the Global Polio Eradication Initiative and draws on platforms like the Global Antimicrobial Resistance Surveillance System and networks including the International Vaccine Institute. Activities include national action plans developed with technical support from World Bank Group instruments, laboratory strengthening modeled after Centers for Disease Control and Prevention cooperative agreements, and stewardship interventions inspired by Johns Hopkins Bloomberg School of Public Health research. Pharmaceutical engagement reflects policy debates seen in negotiations involving World Trade Organization rules, while research partnerships emulate collaborations between Oxford University and industry partners like GlaxoSmithKline and Pfizer.

Global Coordination and Stakeholders

Coordination is led by agencies such as the World Health Organization, the Food and Agriculture Organization of the United Nations, and the World Organisation for Animal Health, in cooperation with multilateral institutions like the World Bank and philanthropic actors including the Wellcome Trust and Bill & Melinda Gates Foundation. National governments from constituencies such as United States, United Kingdom, India, China, and Brazil contribute through ministerial mechanisms similar to the G7 and G20. Civil society and professional bodies—examples include Doctors Without Borders, Royal Society of Medicine, and International Pharmaceutical Federation—participate alongside academic centers like Harvard University, Karolinska Institute, and University of Cape Town.

Monitoring, Evaluation, and Reporting

Monitoring uses surveillance architectures influenced by systems such as the Global Influenza Surveillance and Response System and reporting channels analogous to those of the International Health Regulations (2005). Metrics incorporate indicators recommended by bodies like the Organisation for Economic Co-operation and Development and draw on modelling from groups including Institute for Health Metrics and Evaluation and think tanks like Chatham House. Independent assessments have been undertaken by panels convened similarly to the Lancet Commission and peer review processes affiliated with journals such as The Lancet and Nature Medicine.

Impact, Challenges, and Criticisms

The plan stimulated national action plan adoption across regions represented by African Union and European Union institutions and mobilized resources from entities such as the Global Fund. However, critics from academia and policy circles including voices at Chatham House and Brookings Institution note uneven implementation, financing gaps resembling debates over climate finance, and insufficient incentives for drug development akin to criticisms of pharmaceutical patents under Trade-Related Aspects of Intellectual Property Rights. Challenges include laboratory capacity disparities seen across Sub-Saharan Africa and Southeast Asia, regulatory fragmentation comparable to issues in transnational crime governance, and tensions between stewardship goals and agricultural production priorities articulated by stakeholders from Food and Agriculture Organization of the United Nations member states.

Category:Public health Category:Health policy